

Benzodiazepines: Risks and Options

A Guide for Patients and Prescribers

Cara T. Hoepner, MS, RN, CS, PMHNP-BC — January 2026

At a Glance

What Benzodiazepines Do

Benzodiazepines enhance GABA, the brain's calming neurotransmitter. They work within 20–30 minutes to reduce anxiety, stop panic, relax muscles, and promote sleep. Common examples: alprazolam (Xanax), lorazepam (Ativan), clonazepam (Klonopin), diazepam (Valium).

Key Reasons to Be Cautious

- **Cognitive Impact:** 1,000+ peer-reviewed studies document impaired memory, attention, and multitasking [1]. Benzos may interfere with psychotherapy by blunting emotional processing and fear extinction [2,3].
- **Physical Dependence:** Tolerance and dependence can develop within days to weeks. Withdrawal can be prolonged, lasting months.
- **Falls and Mortality:** In older adults, fall risk increases 20–50% [4] and hip fractures 50–110% [5]. Even low doses are associated with doubled all-cause mortality and potential cancer links with long-term use.
- **Trauma Healing:** Memory formation is central to trauma recovery [6]; benzos can undermine PTSD treatment.

Main Non-Benzo Options

For Anxiety:

- Gabapentin/pregabalin—effective for anxiety with physical symptoms [7,8]
- Propranolol—performance anxiety, test-taking [9]
- Clonidine—hyperadrenergic symptoms: racing heart, sweating, startle [10]
- SSRIs/SNRIs—first-line in many practices (I do not use them; handout available on request)
- Supplements: niacinamide [11], glycine [12,13], L-theanine [14], GABA [15]

For Sleep:

- Trazodone (initiation) [16]
- Gabapentin (maintenance/quality) [17]

- Mirtazapine (initiation, maintenance, quality) [18]
- Orexin antagonists: Belsomra, Quviviq, Dayvigo [19]
- Sleep hygiene and behavioral practices

Behavioral:

- Paced breathing [20,21], meditation [22,23], grounding [24]
- Trauma-informed psychotherapies; limbic system retraining

A Word of Validation

If you are currently taking a benzodiazepine, that does not mean you or your prescriber did anything wrong. For many people, benzos were the best available option at the time. This guide helps you understand benefits and risks so you can make informed decisions going forward.

How This Guide is Organized

Sections cover: mechanism of action, short-term benefits, side effects/risks (cognitive, sleep, mortality, cancer), special populations, withdrawal/tapering, resources, alternatives, and questions for your prescriber. Focus on what's relevant to you.

What Benzodiazepines Are and How They Work

Benzodiazepines are CNS depressants that enhance GABA, the brain's main inhibitory neurotransmitter. GABA acts like a brake—when it binds its receptors, neurons fire less, producing calming and sedating effects [25]. Benzos bind GABA-A receptors and amplify GABA's effect, explaining their rapid onset [25,26].

Key distinctions [27]:

- **Short-acting** (alprazolam, lorazepam): Quick onset, wear off in hours, can cause interdose withdrawal
- **Intermediate-acting** (clonazepam): Longer, steadier coverage
- **Long-acting** (diazepam): Half-lives of a day or more, more stable blood levels

Benzos also have muscle-relaxant, anticonvulsant, and amnesia-producing properties. The same mechanisms that make them acutely effective—rapid onset, strong anxiolytic effects—also drive tolerance, dependence, and cognitive impairment with chronic use.

Short-Term Benefits

In acute distress—panic attacks, severe anxiety, insomnia—benzodiazepines provide rapid relief (20–30 minutes). For panic disorder, having a benzo available can itself reduce anticipatory anxiety. In medical settings, they're valuable for procedures, acute alcohol withdrawal, seizures, and muscle spasms.

Short-term use (days to weeks) carries lower risk. The problem: “short-term” often becomes long-term because benzos work well and the conditions they treat are chronic. Tolerance develops within weeks; psychological and physical dependence can form even with as-prescribed use. What began as relief can shift to needing the medication to feel “normal.” This is not moral failing—it is predictable neurobiology.

Side Effects and Risks

Cognitive Deficits

More than 1,000 peer-reviewed papers document cognitive risks:

- **Attention/Multitasking:** Slowed reactions, increased mistakes—not just driving but cooking, finances, complex instructions [1]
- **Facial Recognition:** Impaired ability to read expressions, especially anger, causing relationship difficulties [28]
- **Memory:** Impaired new learning, processing speed, visuospatial skills [1,29]
- **Synapses and memory:** Long-term daily use over-activates GABA-A receptors in memory-critical regions like the hippocampus, dampening neuroplasticity, reducing dendritic spine density, and weakening long-term potentiation—leading to measurable and sometimes persistent problems with new learning and memory [1,30,31]. In large imaging cohorts, current benzo use is linked to faster hippocampal and amygdala shrinkage [32]. Avoid long-term daily use whenever possible, especially in older adults.
- **Psychotherapy Impact:** Emotional numbing and memory impairment make therapy less effective; benzos impair fear extinction needed for exposure therapy [2,3]
- **Trauma healing:** Use sparingly in people with trauma histories or PTSD—effective trauma therapies work by forming new, non-fear memories, and benzos impair fear-memory extinction and exposure-based learning, worsening PTSD outcomes over time [3,33–35].
- **Persistence:** Deficits may persist >6 months after stopping; some may be permanent [36]

Sleep Architecture

Bedtime benzos worsen all cognitive risks. While they may help you fall/stay asleep, they disrupt sleep architecture:

- **REM Sleep:** Compressed, delayed, reduced quality. REM is crucial for learning/memory [37], cardiovascular health [38], and emotional processing [39]. The amygdala is highly active during REM [40].
- **Slow Wave Sleep:** Reduced delta power. This stage enables glymphatic clearance of waste including amyloid-beta [41]. Microglial inflammation affects BDNF availability, impairing memory [42–45].
- **Overall Quality:** Increased light (stage 2) sleep, reduced restorative sleep [46,47]. You may sleep longer but wake with fatigue and brain fog.

Dementia Risk

Many papers suggest increased Alzheimer's risk with long-term use, often citing anticholinergic effects. However, a 200,000+ subject study found this may not be true [48]. Notably, benzos don't cause typical anticholinergic side effects. The question remains unsettled.

Safety: Accidents

Benzos significantly increase accident risk with automobiles and machinery due to sedation, slowed reactions, and impaired judgment [49].

Mortality

A cohort study (n=5,212) found benzo use—with or without opioids—associated with doubled all-cause mortality vs. low-risk antidepressants for anxiety [50].

Cancer Risk

Long-term use appears to be a significant cancer risk:

- Representative studies: [51–53]
- Kripke et al. (2012) [54]: Even 1–18 pills/year of hypnotics (including benzos and Z-drugs) associated with $>3\times$ death risk (HR 3.60, 95% CI 2.92–4.44)
- Iqbal et al. (2015) [55]: Diazepam, chlordiazepoxide, medazepam, nitrazepam, oxazepam safer; clonazepam higher cancer risk. Increased risk: brain (98%), colorectal (25%), lung (10%)

Important: These are associations, not proof of causation. Unmeasured factors may contribute. But signals are strong enough to minimize duration/dose.

Functional/Occupational Impacts

- **Work:** Cognitive/psychomotor slowing impairs learning, reduces performance, increases errors [56]

- **Healthcare Workers:** Associated with poorer performance and more mistakes [57]
 - **Parenting/Safety-Sensitive Roles:** Raises safety concerns for dependents and public [58]
-

Special Populations

Older Adults

The American Geriatrics Society lists benzos as “potentially inappropriate.” In this population, benzos may:

- Increase fall risk 20–50% [4]
- Increase hip fracture risk 50–110% [5]
- Cause sedation/daytime sleepiness due to pharmacokinetic changes [59]
- Impair cognition subtly-to-moderately [60]
- Double motor vehicle accident risk [61]
- Increase mortality 1.2–3.7× [62–64]

Depression and Self-Harm

Long-term use, particularly clonazepam, may increase depression [65] and suicidality [66].

Trauma and PTSD

VA/DoD, APA, NICE, and others recommend against benzos for PTSD—they don’t improve core symptoms and may worsen recovery or interfere with trauma therapy [35,67–69]. Long-term use can cause progressive behavioral dyscontrol (irritability, aggression, impulsivity), especially with short-acting agents like alprazolam [70,71].

Pregnancy and Breastfeeding

- Possible small increase in orofacial cleft risk [72]
- Risk of “floppy infant” or neonatal withdrawal with late-pregnancy/high-dose use [73]
- Sedation in breastfed infants, especially with other CNS depressants [74]

Addiction Potential

Significant addiction potential, particularly alprazolam [75]. People with substance use disorders are especially prone to misuse [76]. Even as-prescribed use: ~1–2% develop use disorder, ~17% report some misuse [77].

Polysubstance Use

- **Alcohol:** Markedly increased CNS depression, worse mental health outcomes [78]

- **Stimulants:** Signals entrenched polydrug use and greater functional impairment [76,79]
 - **Opioids:** May result in respiratory depression and death [80]
-

If You Are Already Taking a Benzodiazepine

Medicolegal Concerns

Long-term use faces closer scrutiny: PDMPs, duration limits, documentation requirements [81]. New providers may hesitate to continue prescriptions and are expected to re-evaluate indication, review risks/benefits, and discuss deprescribing. Guidelines recommend regular reviews and gradual, individualized tapers—never abrupt discontinuation in dependent patients [82]. Qualitative studies show tighter regulations can leave users feeling abandoned [83].

Withdrawal

Approximately 15 percent of people endure tapers lasting ≥ 1 year. Post-acute withdrawal (PAWS) can last months to years and may include: intense physical/neurological-feeling anxiety, panic attacks, insomnia and fragmented sleep, cognitive impairment ("brain fog"), memory problems, depersonalization/derealization, tinnitus, burning skin sensations, muscle pain and tension, tremors, GI distress, profound fatigue, depression, and emotional blunting. Some people describe it as feeling like their nervous system has been fundamentally destabilized. Symptoms can wax and wane unpredictably, sometimes returning in "waves" long after the taper is complete.

Tapering Approaches:

- Reduce dose by $\sim 10\%$ every 2–4 weeks (from current dose, not original). Adjust slower if needed [81]
- Interdose withdrawal is worse with short-acting benzos (alprazolam, lorazepam). Cross-titration to longer-acting agents often helps [84]
- Some cross-taper to diazepam, then taper off [15]. Avoid in older adults due to long metabolites.
- Fine-tuning: Gram scale for small adjustments; compounded liquid for precise dosing.

Medications That May Assist Tapering:

- **Levetiracetam (Keppra):** Stabilizes GABAergic inhibition [85]. No data for benzo tapers, but I rely on it for this and for stemming tolerance.
- **Pregabalin** [86] **and gabapentin** (lesser degree) [87]
- **Carbamazepine** [88] **and valproate** [86]
- **Oxcarbazepine:** Single study supports use [89]; same active moiety as carbamazepine but more tolerable

Resources for Education and Tapering

Educational/Clinical:

- [The Ashton Manual](#) (diazepam-based taper; substitute as needed). PAWS info: [here](#), [here](#)
- [Oregon Health Authority Tapering Guidelines](#)
- [Inner Compass Guide](#)
- [Benzodiazepine Information Coalition](#)
- [Alliance for Benzodiazepine Best Practices](#)
- [VA/DoD Clinician's Guide to PTSD Medications](#)
- [Canadian Deprescribing Network](#)

Online Community Support:

- [Beating Benzos](#), [Benzodiazepine Recovery](#), [Freedom from Psychiatric Meds](#)
 - [BenzoBuddies](#) (large peer forum), [Benzo Hope](#) (Zoom meetings)
 - [Benzodiazepine Dangers](#), [Benzo Beware](#), [Benzo Hell & Recovery](#)
 - [World Benzodiazepine Awareness Day](#), [Christian Withdrawal Support](#)
-

When Benzodiazepines May Be Appropriate

I consider these medicines put something between the client and the world, attenuating healthy life. I use them judiciously for:

- **Overwhelming circumstances** not responsive to gabapentin/pregabalin and good sleep protocols (temporary)
 - **Panic disorder** while awaiting other treatments, or infrequent PRN for attacks
 - **Activating antidepressants:** Helping through initial SSRI side effects
 - **Night terrors in adults:** Clonazepam for 6 weeks
 - **Catatonia:** Lorazepam 1–2 mg IM/IV; 6–20 mg daily. First-line.
 - **Neuroleptic malignant syndrome:** Lorazepam 1–2 mg IM/IV q4–6h; taper over 10–14 days
 - **Occasional long-term use:** Speeches, flights, BART rides when propranolol doesn't help
-

Alternatives for Anxiety

Gabapentinoids

Excellent for anxiety with physiologic symptoms [7,8], neuropathic pain [90], withdrawal syndromes [86,87]. Helpful with trauma history; gabapentin glues sleep together [17]. Watch for sedation and misuse potential in SUD populations.

- **Gabapentin:** Typically 600 mg TID; I've used up to 4,800–5,400 mg/day. Safe at high doses except in renal impairment.
- **Pregabalin:** 50–900 mg in 2–3 divided doses; usually ~150 mg BID. Far surpasses gabapentin for generalized worry.

Clonidine, Guanfacine, Propranolol

Useful for hyperadrenergic activation (tachycardia, sweating, startle). Caution: hypotension and rebound if stopped abruptly.

- **Clonidine** (much more than guanfacine) **for anxiety:** Best when hyperadrenergic symptoms prominent [10]. Both help emotional regulation (guanfacine > clonidine) [91,92], nightmares [93,94], focus/impulsivity in ADHD [95,96].
- **Propranolol:** Stage fright, specific social anxiety [9]. Some clients drop their benzo after finding propranolol leaves them clear, sharp, calm. Contraindicated in asthma or bradycardia.
- **Combination strategy for panic:** Clonidine or prazosin + propranolol. No data, but can be safely established by starting clonidine/prazosin first, then titrating propranolol while monitoring BP. Many panic treatments exist without SSRIs or benzos—full list available on request.

Quetiapine

Effect size 1.3 in GAD trials [97]. May cause weight gain, diabetes; monitor weight, glucose, lipids [98], prolactin [99]. Increases light sleep, decreases REM [100,101]. Risk of movement disorders [102].

Niacinamide

Facilitates GABA modulation; effects comparable to benzos in some cases despite weak receptor affinity [11]. May raise serotonin via tryptophan sparing [103]. Dose: up to 750 mg 3–4×/day (~2,000–2,500 mg/day); effects typically within 1 week. Nausea/vomiting at ~6,000 mg/day.

Glycine

Modulates excitatory neurotransmission through inhibitory glycine receptors and NMDA glycine site [12,13]. 1–6 g gives relief in ~30 min, lasting ~4 hours.

Amino Acids (GABA and L-Theanine)

- **GABA:** Calming [15]. Available as PharmaGABA (naturally fermented, generally considered more bioavailable) or synthetic GABA. Blends: GABA Calm (Source Naturals), True Calm (NOW Foods).
 - **L-Theanine:** Reduces stress [14], improves attention/executive function [104]. 100–400 mg/dose (typically 200 mg). Helps anxious people focus. Suntheanine is a patented, synthetically produced form that is superior to L-theanine sourced from tea leaves—standardized and reliable batch to batch.
 - I'm not a fan of blends—ingredients aren't individually dosed.
-

Alternatives for Sleep

- **Trazodone:** Initiation, promotes slow wave sleep [16]; safe in obstructive sleep apnea (OSA).
 - **Gabapentin:** Maintenance and quality [17]
 - **Baclofen:** Maintenance, total sleep time, efficiency, slow wave sleep [105]. Anecdotally helps initiation; I prescribe it often.
 - **Mirtazapine:** Efficiency, slow wave, REM, reduces wake-after-sleep-onset [18]. Safe in OSA. Weight gain is near-certain—which worsens OSA.
 - **Clonidine:** Initiation/maintenance in select populations (RLS [106]; postoperative [107]) – and also safe in OSA.
 - **Orexin antagonists** (Belsomra, Quviviq, Dayvigo): Month-over-month improvements in efficiency, latency, wake-after-sleep-onset, total sleep time for full study year [19]. No tolerance, withdrawal, or rebound; sleep architecture preserved [108]. Anecdotally useful for circadian entrainment and jet lag. Safe in OSA.
-

Behavioral Supports

- Paced breathing: Increases parasympathetic/vagal activity and HRV [20,21]
 - Meditation: Vedic/TM [22], mindfulness [23]
 - Grounding techniques [24]
 - Sleep hygiene [109]
 - Trauma-informed psychotherapies (ask for list)
 - Limbic system retraining (ask for resources)
-

Questions to Bring to Your Prescriber

1. What are my non-benzodiazepine options?
2. Could we try a slow reduction plan?
3. How will we monitor thinking, balance, and mood?

4. What's the plan for duration?
 5. What support is available during tapering?
 6. Are there specific risks given my age, history, or other medications?
 7. How might this affect my ability to benefit from therapy?
 8. What should I watch for indicating problems?
 9. What should I do if I need more medication for the same effect?
 10. Can we schedule regular check-ins to reassess?
-

Final Thoughts

Benzodiazepines provide significant short-term relief. For some people in specific circumstances, they remain appropriate. But accumulating evidence on cognitive, physical, and functional risks—especially long-term—requires thoughtful decision-making.

If you're currently taking a benzo, this isn't meant to alarm you. It's meant to inform decisions going forward—continuing, adjusting, tapering, or exploring alternatives—honoring both immediate needs and long-term health.

You deserve collaborative, informed, responsive care. Ask questions, seek second opinions, advocate for what feels right.

Bibliography

1. Crowe SF, Stranks EK. The Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis. *Arch Clin Neuropsychol*. 2018 Nov 1;33(7):901–11.
2. Curran HV, Bond A, O'Sullivan G, Bruce M, Marks I, Lelliot P, Shine P, Lader M. Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder. *Psychol Med*. 1994 Nov;24(4):969–76.
3. Rothbaum BO, Price M, Jovanovic T, Norrholm SD, Gerardi M, Dunlop B, Davis M, Bradley B, Duncan EJ, Rizzo A, Ressler KJ. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. *Am J Psychiatry*. 2014 June;171(6):640–8.
4. Capiou A, Huys L, van Poelgeest E, van der Velde N, Petrovic M, Somers A, EuGMS Task, Finish Group on FRIDs. Therapeutic dilemmas with benzodiazepines and Z-drugs: insomnia and anxiety disorders versus increased fall risk: a clinical review. *Eur Geriatr Med*. 2023 Aug;14(4):697–708.

5. Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. *CNS Drugs*. 2003;17(11):825–37.
6. Damis LF. The Role of Implicit Memory in the Development and Recovery from Trauma-Related Disorders. *NeuroSci*. 2022 Mar;3(1):63–88.
7. Lavigne JE, Heckler C, Mathews JL, Palesh O, Kirshner JJ, Lord R, Jacobs A, Amos E, Morrow GR, Mustian K. A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. *Breast Cancer Res Treat*. 2012 Nov;136(2):479–86.
8. Lydiard RB, Rickels K, Herman B, Feltner DE. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. *Int J Neuropsychopharmacol*. 2010 Mar;13(2):229–41.
9. Elsey JWB, Filmer AI, Galvin HR, Kurath JD, Vossoughi L, Thomander LS, Zavodnik M, Kindt M. Reconsolidation-based treatment for fear of public speaking: a systematic pilot study using propranolol. *Transl Psychiatry*. 2020 June 4;10(1):179.
10. Hoehn-Saric R, Merchant AF, Keyser ML, Smith VK. Effects of clonidine on anxiety disorders. *Arch Gen Psychiatry*. 1981 Nov;38(11):1278–82.
11. Bold JM, Gardner CR, Walker RJ. Central effects of nicotinamide and inosine which are not mediated through benzodiazepine receptors. *Br J Pharmacol*. 1985 Mar;84(3):689–96.
12. Shishkova VN, Николаевна ШВ, Nartcissov YR, Рюрикович НЯ, Titova VY, Юрьевна ТВ, Sheshegova EV, Викторевна ШЕ. Molecular mechanisms defining application of glycine and zinc combination in correction of stress and anxiety main manifestations. *Pharmacy & Pharmacology [Internet]*. 2022 Oct 2 [cited 2025 Dec 20];10(5):404–15. Available from: <https://doi.org/10.19163/2307-9266-2022-10-5-404-415>
13. Wolosker H, Balu DT. D-Serine as the gatekeeper of NMDA receptor activity: implications for the pharmacologic management of anxiety disorders. *Transl Psychiatry*. 2020 June 9;10(1):184.
14. Kimura K, Ozeki M, Juneja LR, Ohira H. L-Theanine reduces psychological and physiological stress responses. *Biol Psychol*. 2007 Jan;74(1):39–45.
15. Abdou AM, Higashiguchi S, Horie K, Kim M, Hatta H, Yokogoshi H. Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans. *Biofactors*. 2006;26(3):201–8.
16. Kaynak H, Kaynak D, Gözükmizi E, Guilleminault C. The effects of trazodone on sleep in patients treated with stimulant antidepressants. *Sleep Med*. 2004 Jan;5(1):15–20.

17. Yeh WC, Lu SR, Wu MN, Lee KW, Chien CF, Fong YO, Li KY, Lai YL, Lin CJ, Li YS, Su CY, Wang YC, Lin YH, Chen TY, Tseng PT, Hsu CY. The impact of antiseizure medications on polysomnographic parameters: a systematic review and meta-analysis. *Sleep Med.* 2021 May;81:319–26.
18. Mi WF, Tabarak S, Wang L, Zhang SZ, Lin X, Du LT, Liu Z, Bao YP, Gao XJ, Zhang WH, Wang XQ, Fan TT, Li LZ, Hao XN, Fu Y, Shi Y, Guo LH, Sun HQ, Liu L, Si TM, Zhang HY, Lu L, Li SX. Effects of agomelatine and mirtazapine on sleep disturbances in major depressive disorder: evidence from polysomnographic and resting-state functional connectivity analyses. *Sleep.* 2020 Nov 12;43(11):zsaa092.
19. Xue T, Wu X, Li J, Chen S, Wang Z, Tan X, Wang Z, Zhang J. Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis. *Front Pharmacol.* 2023;14:1175372.
20. Goncalvez, Paloma, Rafaly Da Silva Pereira, Ana, Da Motta Sempai Coelho, Bianca, Aletti, F, Ricardo Asnati. Effects on Heart Rate Variability and Salivary Cortisol of Slow Paced Breathing for Stress Management | Semantic Scholar. In 2025 [cited 2025 Dec 20]. Available from: <https://www.semanticscholar.org/paper/Effects-on-Heart-Rate-Variability-and-Salivary-of-Gon%C3%A7alves-Aletti/870571df8cf116f99c1401898a9ca2e36f03ceb3>
21. Magnon V, Dutheil F, Vallet GT. Benefits from one session of deep and slow breathing on vagal tone and anxiety in young and older adults. *Sci Rep.* 2021 Sept 29;11(1):19267.
22. Orme-Johnson DW, Barnes VA. Effects of the transcendental meditation technique on trait anxiety: a meta-analysis of randomized controlled trials. *J Altern Complement Med.* 2014 May;20(5):330–41.
23. Zeidan F, Martucci KT, Kraft RA, McHaffie JG, Coghill RC. Neural correlates of mindfulness meditation-related anxiety relief. *Soc Cogn Affect Neurosci.* 2014 June;9(6):751–9.
24. Demierre Berberat P. The Benefits of Grounding Strategies in Emotion and Arousal Regulation. *MHRIJ [Internet].* 2023 Dec 21 [cited 2025 Dec 21];7(2):1–6. Available from: <https://medwinpublishers.com/article-description.php?artId=11561>
25. Goldschen-Ohm MP. Benzodiazepine Modulation of GABAA Receptors: A Mechanistic Perspective. *Biomolecules.* 2022 Nov 30;12(12):1784.
26. Sigel E, Ernst M. The Benzodiazepine Binding Sites of GABAA Receptors. *Trends Pharmacol Sci.* 2018 July;39(7):659–71.
27. Greenblatt DJ, Shader RI, Divoll M, Harmatz JS. Benzodiazepines: a summary of pharmacokinetic properties. *Br J Clin Pharmacol.* 1981;11 Suppl 1(Suppl 1):11S-16S.

28. Garcez H, Fernandes C, Barbosa F, Pereira MR, Silveira C, Marques-Teixeira J, Gonçalves AR. Effects of benzodiazepines administration on identification of facial expressions of emotion: a meta-analysis. *Psychopharmacology (Berl)*. 2020 Jan;237(1):1–9.
29. Rupprecht R, Wetzel CH, Dorostkar M, Herms J, Albert NL, Schwarzbach J, Schumacher M, Neumann ID. Translocator protein (18kDa) TSPO: a new diagnostic or therapeutic target for stress-related disorders? *Mol Psychiatry*. 2022 July;27(7):2918–26.
30. Furukawa T, Nikaido Y, Shimoyama S, Masuyama N, Notoya A, Ueno S. Impaired Cognitive Function and Hippocampal Changes Following Chronic Diazepam Treatment in Middle-Aged Mice. *Front Aging Neurosci*. 2021;13:777404.
31. Bäckström T, Turkmen S, Das R, Doverskog M, Blackburn TP. The GABA system, a new target for medications against cognitive impairment-Associated with neuroactive steroids. *J Intern Med*. 2023 Sept;294(3):281–94.
32. Vom Hofe I, Stricker BH, Vernooij MW, Ikram MK, Ikram MA, Wolters FJ. Benzodiazepine use in relation to long-term dementia risk and imaging markers of neurodegeneration: a population-based study. *BMC Med*. 2024 July 2;22(1):266.
33. Bustos SG, Maldonado H, Molina VA. Disruptive effect of midazolam on fear memory reconsolidation: decisive influence of reactivation time span and memory age. *Neuropsychopharmacology*. 2009 Jan;34(2):446–57.
34. Hart G, Panayi MC, Harris JA, Westbrook RF. Benzodiazepine treatment can impair or spare extinction, depending on when it is given. *Behav Res Ther*. 2014 May;56:22–9.
35. Guina J, Rossetter SR, DeRHODES BJ, Nahhas RW, Welton RS. Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis. *J Psychiatr Pract*. 2015 July;21(4):281–303.
36. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. *Archives of Clinical Neuropsychology [Internet]*. 2004 Apr 1 [cited 2025 Dec 20];19(3):437–54. Available from: <https://www.sciencedirect.com/science/article/pii/S0887617703000969>
37. Nishida M, Pearsall J, Buckner RL, Walker MP. REM sleep, prefrontal theta, and the consolidation of human emotional memory. *Cereb Cortex*. 2009 May;19(5):1158–66.
38. Boudreau P, Yeh WH, Dumont GA, Boivin DB. Circadian variation of heart rate variability across sleep stages. *Sleep*. 2013 Dec 1;36(12):1919–28.
39. Scarpelli S, Bartolacci C, D'Atri A, Gorgoni M, De Gennaro L. The Functional Role of Dreaming in Emotional Processes. *Front Psychol*. 2019;10:459.

40. Muñoz-Torres Z, Velasco F, Velasco AL, Del Río-Portilla Y, Corsi-Cabrera M. Electrical activity of the human amygdala during all-night sleep and wakefulness. *Clin Neurophysiol*. 2018 Oct;129(10):2118–26.
41. Mendelsohn AR, Larrick JW. Sleep facilitates clearance of metabolites from the brain: glymphatic function in aging and neurodegenerative diseases. *Rejuvenation Res*. 2013 Dec;16(6):518–23.
42. Mohammadi M, Manaheji H, Maghsoudi N, Danyali S, Baniasadi M, Zaringhalam J. Microglia dependent BDNF and proBDNF can impair spatial memory performance during persistent inflammatory pain. *Behav Brain Res*. 2020 July 15;390:112683.
43. Schaafsma W, Basterra LB, Jacobs S, Brouwer N, Meerlo P, Schaafsma A, Boddeke EWGM, Eggen BJL. Maternal inflammation induces immune activation of fetal microglia and leads to disrupted microglia immune responses, behavior, and learning performance in adulthood. *Neurobiol Dis*. 2017 Oct;106:291–300.
44. Giordano KR, Green TRF, Opp MR, Rowe RK. Microglial depletion and repopulation differentially modulate sleep and inflammation in a mouse model of traumatic brain injury. *Neurobiol Sleep Circadian Rhythms*. 2025 May;18(Suppl):100115.
45. Ni RJ, Yuan WJ, Wang YY, Yang X, Wei JX, Zhao LS, Wang Q, Tang XD, Ma XH. Microglia-mediated inflammation and synaptic pruning contribute to sleep deprivation-induced mania in a sex-specific manner. *Transl Psychiatry*. 2025 Aug 15;15(1):285.
46. de Mendonça FMR, de Mendonça GPRR, Souza LC, Galvão LP, Paiva HS, de Azevedo Marques Périco C, Torales J, Ventriglio A, Castaldelli-Maia JM, Sousa Martins Silva A. Benzodiazepines and Sleep Architecture: A Systematic Review. *CNS Neurol Disord Drug Targets*. 2023;22(2):172–9.
47. Guina J, Merrill B. Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives. *J Clin Med*. 2018 Jan 30;7(2):17.
48. Osler M, Jørgensen MB. Associations of Benzodiazepines, Z-Drugs, and Other Anxiolytics With Subsequent Dementia in Patients With Affective Disorders: A Nationwide Cohort and Nested Case-Control Study. *Am J Psychiatry*. 2020 June 1;177(6):497–505.
49. Dassanayake T, Michie P, Carter G, Jones A. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. *Drug Saf*. 2011 Feb 1;34(2):125–56.
50. Xu KY, Hartz SM, Borodovsky JT, Bierut LJ, Gruzca RA. Association Between Benzodiazepine Use With or Without Opioid Use and All-Cause Mortality in the United States, 1999-2015. *JAMA Netw Open* [Internet]. 2020 Dec 9 [cited 2025 Dec

20];3(12):e2028557. Available from:
<https://doi.org/10.1001/jamanetworkopen.2020.28557>

51. Kim HB, Myung SK, Park YC, Park B. Use of benzodiazepine and risk of cancer: A meta-analysis of observational studies. *Int J Cancer*. 2017 Feb 1;140(3):513–25.
52. Pottegård A, Friis S, Andersen M, Hallas J. Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study. *Br J Clin Pharmacol*. 2013 May;75(5):1356–64.
53. Zhang T, Yang X, Zhou J, Liu P, Wang H, Li A, Zhou Y. Benzodiazepine drug use and cancer risk: a dose-response meta analysis of prospective cohort studies. *Oncotarget*. 2017 Nov 24;8(60):102381–91.
54. Kripke DF, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study. *BMJ Open* [Internet]. 2012 Feb 27 [cited 2025 Dec 20];2(1):e000850. Available from:
<https://pmc.ncbi.nlm.nih.gov/articles/PMC3293137/>
55. Iqbal U, Nguyen PA, Syed-Abdul S, Yang HC, Huang CW, Jian WS, Hsu MH, Yen Y, Li YC (Jack). Is Long-term Use of Benzodiazepine a Risk for Cancer? *Medicine (Baltimore)* [Internet]. 2015 Feb 13 [cited 2025 Dec 20];94(6):e483. Available from:
<https://pmc.ncbi.nlm.nih.gov/articles/PMC4602739/>
56. Zetsen SPG, Schellekens AFA, Paling EP, Kan CC, Kessels RPC. Cognitive Functioning in Long-Term Benzodiazepine Users. *Eur Addict Res*. 2022;28(5):377–81.
57. Roncero C, Bravo-Grande JL, Andrés-Olivera P, Peña M, Treceño C, González-Pelaez P, Aguilar L, Remón-Gallo D, González-Sánchez A. Benzodiazepine Misuse Among Health Care Workers: The Effect of Sleep Disorders on Work Performance. *J Clin Med*. 2025 June 16;14(12):4266.
58. Garbarino S, Lanteri P, Bragazzi NL, Gualerzi G, Riccò M. Occupational Injuries and Use of Benzodiazepines: A Systematic Review and Metanalysis. *Front Hum Neurosci*. 2021;15:629719.
59. Madhusoodanan S, Bogunovic OJ. Safety of benzodiazepines in the geriatric population. *Expert Opin Drug Saf*. 2004 Sept;3(5):485–93.
60. Chandramouleeshwaran S, Khan WU, Inglis F, Rajji TK. Impact of psychotropic medications on cognition among older adults: a systematic review. *Int Psychogeriatr*. 2024 Dec;36(12):1110–27.
61. Thomas RE. Benzodiazepine use and motor vehicle accidents. Systematic review of reported association. *Can Fam Physician*. 1998 Apr;44:799–808.

62. Mathieu C, Joly P, Jacqmin-Gadda H, Wanneveich M, Bégaud B, Pariente A. Patterns of Benzodiazepine Use and Excess Risk of All-Cause Mortality in the Elderly: A Nationwide Cohort Study. *Drug Saf.* 2021 Jan;44(1):53–62.
63. Davies SJ, Rudoler D, de Oliveira C, Huang A, Kurdyak P, Iaboni A. Comparative safety of chronic versus intermittent benzodiazepine prescribing in older adults: A population-based cohort study. *J Psychopharmacol.* 2022 Apr;36(4):460–9.
64. Davenport, Liam. Intermittent Use of Benzodiazepines Is the Safest Option [Internet]. Medscape. 2023 [cited 2025 Dec 20]. Available from: <https://www.medscape.com/viewarticle/997282>
65. Sun CF, Pola AS, Su KP, Lin BY, Kablinger AS, Trestman RL. Benzodiazepine use for anxiety disorders is associated with increased long-term risk of mood and substance use disorders: A large-scale retrospective cohort study. *Drug Alcohol Depend Rep.* 2024 Sept;12:100270.
66. Dodds TJ. Prescribed Benzodiazepines and Suicide Risk: A Review of the Literature. *Prim Care Companion CNS Disord.* 2017 Mar 2;19(2).
67. Jeffreys M, Capehart B, Friedman MJ. Pharmacotherapy for posttraumatic stress disorder: review with clinical applications. *J Rehabil Res Dev.* 2012;49(5):703–15.
68. Guideline Development Panel for the Treatment of PTSD in Adults, American Psychological Association. Summary of the clinical practice guideline for the treatment of posttraumatic stress disorder (PTSD) in adults. *Am Psychol.* 2019;74(5):596–607.
69. Campos B, Vinder V, Passos RBF, Coutinho ESF, Vieira NCP, Leal KB, Mendlowicz MV, Figueira I, Luz MP, Marques-Portela C, Vilete LMP, Berger W. To BDZ or not to BDZ? That is the question! Is there reliable scientific evidence for or against using benzodiazepines in the aftermath of potentially traumatic events for the prevention of PTSD? A systematic review and meta-analysis. *J Psychopharmacol.* 2022 Apr;36(4):449–59.
70. Albrecht B, Staiger PK, Hall K, Miller P, Best D, Lubman DI. Benzodiazepine use and aggressive behaviour: a systematic review. *Aust N Z J Psychiatry.* 2014 Dec;48(12):1096–114.
71. Bond AJ, Curran HV, Bruce MS, O'Sullivan G, Shine P. Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam. *J Affect Disord.* 1995 Dec 13;35(3):117–23.
72. Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. *BMJ.* 1998 Sept 26;317(7162):839–43.

73. McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. *Reprod Toxicol*. 1994;8(6):461–75.
74. Kelly LE, Poon S, Madadi P, Koren G. Neonatal benzodiazepines exposure during breastfeeding. *J Pediatr*. 2012 Sept;161(3):448–51.
75. Diaz L, Eiden C, Jouanjus E, Frauger E, Fouilhé N, Djeddar S, Gibaja V, Boucher A, Le Boisselier R, Libert F, Caous AS, Monzon E, Guerlais M, Daveluy A, Fauconneau B, Peyrière H. Alprazolam misuse: Analysis of French Addictovigilance Network data from 2011 to 2020. *Thérapie*. 2023;78(6):647–57.
76. Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: A systematic review. *Drug Alcohol Depend*. 2019 July 1;200:95–114.
77. Blanco C, Han B, Jones CM, Johnson K, Compton WM. Prevalence and Correlates of Benzodiazepine Use, Misuse, and Use Disorders Among Adults in the United States. *J Clin Psychiatry*. 2018 Oct 16;79(6):18m12174.
78. Brandt J, Leong C. Benzodiazepines and Z-Drugs: An Updated Review of Major Adverse Outcomes Reported on in Epidemiologic Research. *Drugs R D*. 2017 Dec;17(4):493–507.
79. Darke S, Ross J, Cohen J. The use of benzodiazepines among regular amphetamine users. *Addiction*. 1994 Dec;89(12):1683–90.
80. Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. *Drug Alcohol Depend*. 2012 Sept 1;125(1–2):8–18.
81. Brunner E, Chen CYA, Klein T, Maust D, Mazer-Amirshahi M, Mecca M, Najera D, Ogbonna C, Rajneesh KF, Roll E, Sanders AE, Snodgrass B, VandenBerg A, Wright T, Boyle M, Devoto A, Framnes-DeBoer S, Kleykamp B, Norrington J, Lindsay D, Clinical Guideline Committee (CGC) Members, ASAM Staff and Contractors. Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits. *J Gen Intern Med*. 2025 Sept;40(12):2814–59.
82. Guina J, Merrill B. Benzodiazepines II: Waking Up on Sedatives: Providing Optimal Care When Inheriting Benzodiazepine Prescriptions in Transfer Patients. *J Clin Med*. 2018 Jan 30;7(2):20.
83. Krüger C, Lindberg MH, Burmester S, Franck J, Westman J. Experiences of long-term benzodiazepine use and addiction amid changes in guidelines for the prescription of narcotic drugs: a qualitative study. *BMC Public Health*. 2025 Aug 5;25(1):2652.
84. Cosci F, Chouinard G. Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications. *Psychother Psychosom*. 2020;89(5):283–306.

85. Palma E, Roseti C, Maiolino F, Fucile S, Martinello K, Mazzuferi M, Aronica E, Manfredi M, Esposito V, Cantore G, Miledi R, Simonato M, Eusebi F. GABA(A)-current rundown of temporal lobe epilepsy is associated with repetitive activation of GABA(A) "phasic" receptors. *Proc Natl Acad Sci U S A*. 2007 Dec 26;104(52):20944–8.
86. Baandrup L, Ebdrup BH, Rasmussen JØ, Lindschou J, Gluud C, Glenthøj BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. *Cochrane Database Syst Rev*. 2018 Mar 15;3(3):CD011481.
87. Alzghoul H, Al-Said MI, Obeidat O, Al-Ani H, Tarawneh M, Meadows R, Youness H, Reddy R, Al-Jafari M, Alzghoul BN, Khan A. Effectiveness of Gabapentin as a Benzodiazepine-Sparing Agent in Alcohol Withdrawal Syndrome. *Medicina (Kaunas)*. 2024 June 19;60(6):1004.
88. Welsh JW, Tretyak V, McHugh RK, Weiss RD, Bogunovic O. Review: Adjunctive pharmacologic approaches for benzodiazepine tapers. *Drug Alcohol Depend*. 2018 Aug 1;189:96–107.
89. Croissant B, Grosshans M, Diehl A, Mann K. Oxcarbazepine in rapid benzodiazepine detoxification. *Am J Drug Alcohol Abuse*. 2008;34(5):534–40.
90. Mayoral V, Galvez R, Ferrándiz M, Miguéns Vázquez X, Cordero-García C, Alcántara Montero A, Pérez C, Pérez-Páramo M. Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety. *Front Pain Res (Lausanne)*. 2024;5:1513597.
91. Burek GA, Waite MR, Heslin K, Liewen AK, Yaqub TM, Larsen SE. Low-dose clonidine in veterans with Posttraumatic stress disorder. *J Psychiatr Res*. 2021 May;137:480–5.
92. Mori H, Ochi S, Hashida H, Iga JI, Ueno SI. Efficacy of Guanfacine for Self-injurious and Aggressive Behaviors through the Reduction of Impulsivity in Borderline Personality Disorder: Two Case Reports and a Literature Review. *Clin Psychopharmacol Neurosci*. 2025 Aug 31;23(3):520–5.
93. Bange JS, Melvin KE. Clonidine Use for the Treatment of Nightmares in Posttraumatic Stress Disorder. *Case Rep Psychiatry*. 2022;2022:5251406.
94. Jagtiani A, Gandhi R, Banga A, Blacker J, Joshi R, Bollu B, Kashyap R. Alpha-2 Agonists in Children and Adolescents With Post-traumatic Stress Disorder: A Systematic Review. *Cureus*. 2024 Jan;16(1):e53009.
95. Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. *J Am Acad Child Adolesc Psychiatry*. 2014 Feb;53(2):153–73.

96. Fernando ABP, Economidou D, Theobald DE, Zou MF, Newman AH, Spoelder M, Caprioli D, Moreno M, Hipólito L, Aspinall AT, Robbins TW, Dalley JW. Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists. *Psychopharmacology (Berl)*. 2012 Jan;219(2):341–52.
97. Maneeton N, Maneeton B, Woottituk P, Likhitsathian S, Suttajit S, Boonyanaruthee V, Srisurapanont M. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. *Drug Des Devel Ther*. 2016;10:259–76.
98. Hasnain M, Vieweg WVR, Hollett B. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. *Postgrad Med*. 2012 July;124(4):154–67.
99. Khan N, Orange R. A Clinical Re-Audit (Cycle 1) on the Monitoring and Management of Antipsychotic-Induced Hyperprolactinaemia. *BJPsych Open* [Internet]. 2025 June 20 [cited 2025 Dec 20];11(Suppl 1):S251. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC12260709/>
100. Cohrs S, Rodenbeck A, Guan Z, Pohlmann K, Jordan W, Meier A, Rüther E. Sleep-promoting properties of quetiapine in healthy subjects. *Psychopharmacology (Berl)*. 2004 July;174(3):421–9.
101. Monti JM, Torterolo P, Pandi Perumal SR. The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia. *Sleep Med Rev*. 2017 June;33:51–7.
102. Martino D, Karnik V, Osland S, Barnes TRE, Pringsheim TM. Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis. *Can J Psychiatry*. 2018 Jan 1;63(11):706743718777392.
103. Hwang ES, Song SB. Possible Adverse Effects of High-Dose Nicotinamide: Mechanisms and Safety Assessment. *Biomolecules*. 2020 Apr 29;10(5):687.
104. Baba Y, Inagaki S, Nakagawa S, Kaneko T, Kobayashi M, Takihara T. Effects of l-Theanine on Cognitive Function in Middle-Aged and Older Subjects: A Randomized Placebo-Controlled Study. *J Med Food*. 2021 Apr;24(4):333–41.
105. Raad S, Wilkerson M, Jones KR, Orr WC. The effect of baclofen on objective and subjective sleep measures in a model of transient insomnia. *Sleep Med*. 2020 Aug;72:130–4.
106. Wagner ML, Walters AS, Coleman RG, Hening WA, Grasing K, Chokroverty S. Randomized, Double-Blind, Placebo-Controlled Study of Clonidine in Restless Legs Syndrome. *Sleep*. 1996 Jan;19(1):52–8.

107. Liu D, Hallt E, Platz A, Humblet A, Lassig-Smith M, Stuart J, Fourie C, Livermore A, McConnochie BY, Starr T, Herbst K, Woods CA, Pincus JM, Reade MC. Low-dose clonidine infusion to improve sleep in postoperative patients in the high-dependency unit. A randomised placebo-controlled single-centre trial. *Intensive Care Med.* 2024 Nov;50(11):1873–83.
108. Kishi T, Ikuta T, Citrome L, Sakuma K, Hatano M, Hamanaka S, Nishii Y, Iwata N. Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. *Transl Psychiatry.* 2025 June 24;15(1):211.
109. Scott AJ, Webb TL, Martyn-St James M, Rowse G, Weich S. Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials. *Sleep Med Rev.* 2021 Dec;60:101556.